NO20020176L - Cyclic peptide derivatives as inhibitors of intergrin <alfa> v <beta> 6 - Google Patents
Cyclic peptide derivatives as inhibitors of intergrin <alfa> v <beta> 6Info
- Publication number
- NO20020176L NO20020176L NO20020176A NO20020176A NO20020176L NO 20020176 L NO20020176 L NO 20020176L NO 20020176 A NO20020176 A NO 20020176A NO 20020176 A NO20020176 A NO 20020176A NO 20020176 L NO20020176 L NO 20020176L
- Authority
- NO
- Norway
- Prior art keywords
- phe
- peptide derivatives
- intergrin
- alfa
- inhibitors
- Prior art date
Links
- 108010069514 Cyclic Peptides Proteins 0.000 title 1
- 102000001189 Cyclic Peptides Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Oppfinnelsen vedrører nye peptidderivater med formel (I): syklo-(Arg-X'-Asp-X2-X3-X4-X5-X6-R1); som er biologisk aktive som Ugander for integrin avp6) X1 er Ser, Gly eller Thr; X2 er Leu, Ile, Nle, Val eller Phe; X3 er Asp, Glu, Lys eller Phe; X4 er Gly, Ala eller Ser; X5 er Leu, Ile, Nle, Val eller Phe; X6 er Arg, Har eller Lys; og R1 er utelatt eller er ett eller flere co-amino- karboksylsyreradikaler, hvor o-aminokarboksyl- syreradikalet eller -radikalene er fra 500 til 2500 pm lange. Aminosyrene kan også være derivatisert og D- og L-formene av de optisk aktive aminosyreradikalene er omfattet. Oppfinnelsen vedrører også de fysiologisk egnede salter og solvater av derivatene ifølge oppfinnelsen.The invention relates to novel peptide derivatives of formula (I): cyclo- (Arg-X'-Asp-X2-X3-X4-X5-X6-R1); which are biologically active as Ugander for integrin avp6) X1 is Ser, Gly or Thr; X 2 is Leu, Ile, Nle, Val or Phe; X3 is Asp, Glu, Lys or Phe; X 4 is Gly, Ala or Ser; X5 is Leu, Ile, Nle, Val or Phe; X6 is Arg, Har or Lys; and R1 is omitted or is one or more co-amino carboxylic acid radicals, wherein the o-amino carboxylic acid radical or radicals are from 500 to 2500 µm long. The amino acids may also be derivatized and the D and L forms of the optically active amino acid radicals are included. The invention also relates to the physiologically suitable salts and solvates of the derivatives according to the invention.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19933173A DE19933173A1 (en) | 1999-07-15 | 1999-07-15 | Cyclic peptide derivatives as inhibitors of the integrin alpha¶v¶beta¶6¶ |
| PCT/EP2000/006188 WO2001005810A2 (en) | 1999-07-15 | 2000-07-03 | CYCLIC PEPTIDE DERIVATIVES AS INHIBITORS OF INTEGRIN αVβ¿6? |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20020176L true NO20020176L (en) | 2002-01-14 |
| NO20020176D0 NO20020176D0 (en) | 2002-01-14 |
Family
ID=7914891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20020176A NO20020176D0 (en) | 1999-07-15 | 2002-01-14 | Cyclic peptide derivatives as inhibitors of intergrin <alfa> v <beta> 6 |
Country Status (23)
| Country | Link |
|---|---|
| EP (2) | EP1196433B1 (en) |
| JP (1) | JP2003505395A (en) |
| KR (1) | KR20020010928A (en) |
| CN (1) | CN1361792A (en) |
| AR (1) | AR024742A1 (en) |
| AT (1) | ATE340803T1 (en) |
| AU (1) | AU772782C (en) |
| BR (1) | BR0012418A (en) |
| CA (1) | CA2379022A1 (en) |
| CZ (1) | CZ200226A3 (en) |
| DE (2) | DE19933173A1 (en) |
| DK (1) | DK1196433T3 (en) |
| ES (1) | ES2273703T3 (en) |
| HK (1) | HK1048641A1 (en) |
| HU (1) | HUP0201925A3 (en) |
| MX (1) | MXPA02000465A (en) |
| NO (1) | NO20020176D0 (en) |
| PL (1) | PL354363A1 (en) |
| PT (1) | PT1196433E (en) |
| SK (1) | SK262002A3 (en) |
| TW (1) | TWI226890B (en) |
| WO (1) | WO2001005810A2 (en) |
| ZA (1) | ZA200201275B (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002232176B2 (en) * | 2001-02-19 | 2006-06-15 | Takara Bio Inc. | Cyclic peptide |
| DE10118550A1 (en) * | 2001-04-14 | 2002-10-17 | Merck Patent Gmbh | New 3-ethanoylamino-3-phenyl-propionic acid derivatives, are integrin agonists or antagonists useful e.g. for treating angiogenic, cardiovascular, inflammatory, osteolytic or tumor diseases or infections |
| US7538084B2 (en) | 2003-03-17 | 2009-05-26 | Amr Technology, Inc. | Cyclosporins |
| ATE399542T1 (en) * | 2003-10-01 | 2008-07-15 | Merck Patent Gmbh | ALFAVBETA3 AND ALFAVBETA6 INTEGRIN ANTAGONISTS AS ANTIFIBROTIC AGENTS |
| ES2436170T3 (en) * | 2003-12-03 | 2013-12-27 | The Scripps Research Institute | Antibodies and peptides specific for integrin alfa II beta3 |
| JP2008514701A (en) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | Cyclosporine alkyne analogs and their pharmaceutical use |
| JP2008514702A (en) | 2004-09-29 | 2008-05-08 | エーエムアール テクノロジー インコーポレイテッド | Novel cyclosporine analogues and their pharmaceutical use |
| JP2008515886A (en) | 2004-10-06 | 2008-05-15 | エーエムアール テクノロジー インコーポレイテッド | Cyclosporine alkynes and their usefulness as medical drugs |
| GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| EP2064244B1 (en) | 2006-08-03 | 2019-06-05 | MedImmune Limited | ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF |
| EP2784511A1 (en) | 2013-03-27 | 2014-10-01 | Universität Zürich | Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma |
| SI3350222T1 (en) | 2015-09-18 | 2022-01-31 | Technische Universitaet Muenchen | Ligands for integrin avbeta6, synthesis and uses thereof |
| MA52117A (en) | 2017-02-28 | 2022-04-06 | Morphic Therapeutic Inc | INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6) |
| MX394210B (en) | 2017-02-28 | 2025-03-04 | Morphic Therapeutic Inc | Inhibitors of (alpha-v)(beta-6) integrin |
| US11332498B2 (en) | 2017-03-17 | 2022-05-17 | Technische Universitat Munchen | Ligands for integrin αVβ8, synthesis and uses thereof |
| GB201706472D0 (en) * | 2017-04-24 | 2017-06-07 | Cancer Res Tech Ltd | Tumour-targeting peptide variants |
| WO2020047208A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
| WO2020047239A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
| SI3844162T1 (en) | 2018-08-29 | 2025-06-30 | Morphic Therapeutic, Inc. | Inhibitors of alpha v beta6 integrin |
| WO2021180969A1 (en) * | 2020-03-12 | 2021-09-16 | Technische Universität München | Cyclic peptides and their conjugates for addressing alpha-v-beta-6 integrin in vivo |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4472305A (en) | 1983-05-17 | 1984-09-18 | Sterling Drug Inc. | Hexapeptide amides |
| DE4310643A1 (en) | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Cyclic adhesion inhibitors |
| DE19538741A1 (en) | 1995-10-18 | 1997-04-24 | Merck Patent Gmbh | Cyclopeptide derivatives |
| CZ20012212A3 (en) * | 1998-12-19 | 2001-09-12 | Merck Patent Gmbh | Peptidic compound, use thereof and pharmaceutical preparation in which the compound is comprised |
-
1999
- 1999-07-15 DE DE19933173A patent/DE19933173A1/en not_active Withdrawn
-
2000
- 2000-07-03 KR KR1020017015995A patent/KR20020010928A/en not_active Withdrawn
- 2000-07-03 MX MXPA02000465A patent/MXPA02000465A/en unknown
- 2000-07-03 DE DE50013525T patent/DE50013525D1/en not_active Expired - Fee Related
- 2000-07-03 CZ CZ200226A patent/CZ200226A3/en unknown
- 2000-07-03 HK HK03100378.9A patent/HK1048641A1/en unknown
- 2000-07-03 SK SK26-2002A patent/SK262002A3/en unknown
- 2000-07-03 HU HU0201925A patent/HUP0201925A3/en unknown
- 2000-07-03 CA CA002379022A patent/CA2379022A1/en not_active Abandoned
- 2000-07-03 PL PL00354363A patent/PL354363A1/en unknown
- 2000-07-03 AU AU58236/00A patent/AU772782C/en not_active Ceased
- 2000-07-03 BR BR0012418-4A patent/BR0012418A/en not_active Application Discontinuation
- 2000-07-03 CN CN00810415A patent/CN1361792A/en active Pending
- 2000-07-03 WO PCT/EP2000/006188 patent/WO2001005810A2/en not_active Ceased
- 2000-07-03 PT PT00943971T patent/PT1196433E/en unknown
- 2000-07-03 EP EP00943971A patent/EP1196433B1/en not_active Expired - Lifetime
- 2000-07-03 DK DK00943971T patent/DK1196433T3/en active
- 2000-07-03 AT AT00943971T patent/ATE340803T1/en not_active IP Right Cessation
- 2000-07-03 JP JP2001511467A patent/JP2003505395A/en active Pending
- 2000-07-03 ES ES00943971T patent/ES2273703T3/en not_active Expired - Lifetime
- 2000-07-03 EP EP06019918A patent/EP1754714A1/en not_active Withdrawn
- 2000-07-13 TW TW089113997A patent/TWI226890B/en not_active IP Right Cessation
- 2000-07-14 AR ARP000103621A patent/AR024742A1/en unknown
-
2002
- 2002-01-14 NO NO20020176A patent/NO20020176D0/en unknown
- 2002-02-14 ZA ZA200201275A patent/ZA200201275B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ200226A3 (en) | 2002-04-17 |
| JP2003505395A (en) | 2003-02-12 |
| KR20020010928A (en) | 2002-02-06 |
| MXPA02000465A (en) | 2002-07-30 |
| DK1196433T3 (en) | 2007-02-12 |
| HK1048641A1 (en) | 2003-04-11 |
| CA2379022A1 (en) | 2001-01-25 |
| PL354363A1 (en) | 2004-01-12 |
| TWI226890B (en) | 2005-01-21 |
| ES2273703T3 (en) | 2007-05-16 |
| EP1196433B1 (en) | 2006-09-27 |
| AU772782C (en) | 2005-01-27 |
| AU5823600A (en) | 2001-02-05 |
| AU772782B2 (en) | 2004-05-06 |
| PT1196433E (en) | 2007-01-31 |
| DE19933173A1 (en) | 2001-01-18 |
| NO20020176D0 (en) | 2002-01-14 |
| CN1361792A (en) | 2002-07-31 |
| ZA200201275B (en) | 2003-08-22 |
| BR0012418A (en) | 2002-03-26 |
| HUP0201925A2 (en) | 2002-10-28 |
| HUP0201925A3 (en) | 2002-11-28 |
| EP1754714A1 (en) | 2007-02-21 |
| ATE340803T1 (en) | 2006-10-15 |
| AR024742A1 (en) | 2002-10-23 |
| WO2001005810A2 (en) | 2001-01-25 |
| DE50013525D1 (en) | 2006-11-09 |
| WO2001005810A3 (en) | 2001-05-17 |
| SK262002A3 (en) | 2002-07-02 |
| EP1196433A2 (en) | 2002-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20020176L (en) | Cyclic peptide derivatives as inhibitors of intergrin <alfa> v <beta> 6 | |
| AU2007258387B2 (en) | Peptide fragments for inducing synthesis of extracellular matrix proteins | |
| CA1341336C (en) | Neuropeptide y agonists | |
| FI68246B (en) | ANALOGIFICATION OF CYCLOPEPTIDES FRAMSTAELLNING AV NYA | |
| DE60031999D1 (en) | Stabilized Liquid Pharmaceutical Composition Containing Polypeptids | |
| IT1196500B (en) | MALONIC ACID DERIVATIVES AND METHODS FOR THEIR SYNTHESIS | |
| DE69942035D1 (en) | HUMAN PARATHYROIDHORMONE, MODIFICATIONS, MANUFACTURE AND USE | |
| SE448461B (en) | NEW PEPTIDYL ARGINALDEHYDE DERIVATIVES ALSO SET FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | |
| IE51259B1 (en) | Angiotensin converting enzyme inhibitors | |
| AR006517A1 (en) | POLYPEPTIDE THAT REACHES A TOTAL AROUND 30 AMINO ACIDS; RESULTANT SUBSTANCE, PEPTIDOMIMETICO AND PHARMACEUTICAL COMPOSITION; USES OF THE POLYPEPTIDE AND PROCESS FOR THE SYNTHESIS OF THE POLYPEPTIDE. | |
| IT1227907B (en) | PROCEDURE FOR THE SYNTHESIS OF RETRO-REVERSE AND NEW INTERMEDIATE PEPTIDES IN THIS PROCEDURE | |
| DK0479912T3 (en) | Method for inhibiting the course of N-end rule in living cells | |
| Robl et al. | Dual metalloprotease inhibitors. I. Constrained peptidomimetics of mercaptoacyl dipeptides | |
| JP6548126B2 (en) | Type III collagen production promoter | |
| NO955067L (en) | FVII / TF peptides | |
| ATE248806T1 (en) | N-3, 3-DIMETHYLBUTYL-L-ASPARAGIC ACID AND THEIR ESTERS, METHOD FOR PRODUCING SAME AND THE PROCESS FOR THEREOF N-(N-(3,3-DIMETHYLBUTYL)-L-ALPHA-ASPARTYL)-L-PHENYLALANINE-1- TO PRODUCE METHYL ESTER | |
| ATE245168T1 (en) | PEPTIDES THAT EXHIBIT ANTI-CELL ADHESION ACTIVITY | |
| US5395823A (en) | Neuropeptide Y agonists and partial agonists | |
| NO20016341L (en) | Inhibitors for the integrin <alfa> v <beta> 6 | |
| WO1998040091A1 (en) | Microbicidal peptides and methods of use | |
| Sugano et al. | Studies of peptide antibiotics. XXX. Syntheses of gramicidin S analogs containing N-methylleucine in place of leucine | |
| CA2146367C (en) | Calcium channel blocking polypeptides from heteropoda venatoria | |
| WO2002083729A3 (en) | Polypeptides derived from amyloid precursor peptide (app) and their uses | |
| EP2300610A1 (en) | Novel bmp-12-related proteins and methods of their manufacture | |
| DE60324936D1 (en) | BICYCLIC OLIGOPEPTIDES AND THEIR USE AS GLUCAGON RECEPTOR ANTAGONIST |